sTNFR1 Test

sTNFR1 accurately identifies diabetic patients at high risk of progression to esrd

- Improve patient management
- Standard assay format
- 50 μL serum or plasma
- Accurate & reliable quantification of sTNFr1
20 years after onset of overt nephropathy, ~20% of diabetes patients will have progressed to ESRD [6]

Early detection of diabetic patients that are high-risk for ESRD. Improve Patient Management. Reduce costs and save time.

The EKF sTNFR1 Test is a standard ELISA assay that allows for early and accurate identification of diabetic patients who are at high risk of progression to end stage renal disease (ESRD), representing the potential for significant improvement in patient management and outcomes.

The sTNFR1 test accurately and reliably detects circulating levels of Soluble Tumor Necrosis Factor receptor 1 (sTNFR1) in patient samples. Recent research has demonstrated that high circulating levels of sTNFR1 were strongly associated with progression to ESRD in patients both with and without overt nephropathy.

<table>
<thead>
<tr>
<th>Advanced Detection</th>
<th>• Identifies patients at risk of progression to ESRD up to 10 years in advance of currently available tests.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Easy-to-use</td>
<td>• Minimal training required. Uses standard laboratory equipment.</td>
</tr>
<tr>
<td>Small Sample Quantity</td>
<td>• Requires 50 μl Serum or Plasma.</td>
</tr>
<tr>
<td>Accurate &amp; Reliable</td>
<td>• Uses Monoclonal Antibodies to give accurate results in 4.5 hours. Minimal interference and no cross reactivity with sTNFR2.</td>
</tr>
<tr>
<td>Improve Patient Management</td>
<td>• Allows clinicians to identify patients who need the most care. Reduces costs and potentially saves time.</td>
</tr>
</tbody>
</table>

References
Risk of ESRD and All Cause Mortality in Type 2 Diabetes According to Circulating Levels of FGF-23 and TNFR1.

Baseline Markers of Inflammation Are Associated With Progression to Macroalbuminuria in Type 1 Diabetic Subjects.

Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 Diabetes.

Circulating TNF Receptors 1 and 2 Predict Stage 3 CKD in Type 1 Diabetes.

Serum Concentrations of Markers of TNFα and Fas-Mediated Pathways and Renal Function in Nonproteinuric Patients with Type 1 Diabetes.